Sara Asensio Peña

Dr. Sara Asensio Peña

Research Institute Hospital 12 de Octubre, Madrid, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2017 in BMC Genomics
Verified
Journal Article
Open access
PDF file
Alfredo SantallaAlfredo Santalla
Alfredo Santalla
Gisela Nogales-GadeaGisela Nogales-Gadea
Gisela Nogales-Gadea
AEAlberto Blazquez Encinar
Alberto Blazquez Encinar
IVIrene Vieitez
Irene Vieitez
AGAdrián González-Quintana
Adrián González-Quintana
Alejandro LuciaAlejandro Lucia
Alejandro Lucia
We recently described the genotype/phenotype features of all Spanish patients diagnosed with McArdle disease as of January 2011 (n = 239, prevalence of ~1/167,000) (J Neurol Neurosurg Psychiatry 2012;83:322–8). Several caveats were however identified suggesting that the prevalence of the disease is actually higher. We have now updated main genotype/phenotype data, as well as potential associations within/between them, of all Spanish individuals currently diagnosed with McArdle disease (December 2016). Ninety-four new patients (all Caucasian) have been diagnosed, yielding a prevalence of ~1/139,543 individuals. Around 55% of the mutated alleles have the commonest PYGM pathogenic mutation p.R50X, whereas p.W798R and p.G205S account for 10 and 9% of the allelic variants, respectively. Seven new mutations were identified: p.H35R, p.R70C, p.R94Q, p.L132WfsX163, p.Q176P, p.R576Q, and c.244-3_244-2CA. Almost all patients show exercise intolerance, the second wind phenomenon and high serum creatine kinase activity. There is, however, heterogeneity in clinical severity, with 8% of patients being asymptomatic during normal daily life, and 21% showing limitations during daily activities and fixed muscle weakness. A major remaining challenge is one of diagnosis, which is often delayed until the third decade of life in 72% of new patients despite the vast majority (86%) reporting symptoms before 20 years. An important development is the growing proportion of those reporting a 4-year improvement in disease severity (now 34%) and following an active lifestyle (50%). Physically active patients are more likely to report an improvement after a 4-year period in the clinical course of the disease than their inactive peers (odds ratio: 13.98; 95% confidence interval: 5.6, 34.9; p < 0.001). Peak oxygen uptake is also higher in the former (20.7 ± 6.0 vs. 16.8 ± 5.3 mL/kg/min, p = 0.0013). Finally, there is no association between PYGM genotype and phenotype manifestation of the disease. The reported prevalence of McArdle disease grows exponentially despite frequent, long delays in genetic diagnosis, suggesting that many patients remain undiagnosed. Until a genetic cure is available (which is not predicted in the near future), current epidemiologic data support that adoption of an active lifestyle is the best medicine for these patients.

16 July 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
IGInés García-Consuegra
Inés García-Consuegra
Sara Asensio PeñaSara Asensio Peña
Sara Asensio Peña
ABAlfonsina Ballester-Lopez
Alfonsina Ballester-Lopez
RFRosario Francisco-Velilla
Rosario Francisco-Velilla
TPTomás Pinos
Tomás Pinos
Miguel A. MartinMiguel A. Martin
Miguel A. Martin

31 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
EPElena Prieto-García
Elena Prieto-García
CDC. Vanesa Díaz-García
C. Vanesa Díaz-García
AAAlba Agudo-López
Alba Agudo-López
VPVirginia Pardo-Marqués
Virginia Pardo-Marqués
IGInés García-Consuegra
Inés García-Consuegra
MAM. Teresa Agulló-Ortuño
M. Teresa Agulló-Ortuño
One key feature of pancreatic ductal adenocarcinoma (PDAC) is a dense desmoplastic reaction that has been recognized as playing important roles in metastasis and therapeutic resistance. We aim to study tumor–stromal interactions in an in vitro coculture model between human PDAC cells (Capan-1 or PL-45) and fibroblasts (LC5). Confocal immunofluorescence, Enzyme-Linked Immunosorbent Assay (ELISA), and Western blotting were used to evaluate the expressions of activation markers; cytokines arrays were performed to identify secretome profiles associated with migratory and invasive properties of tumor cells; extracellular vesicle production was examined by ELISA and transmission electron microscopy. Coculture conditions increased FGF-7 secretion and α-SMA expression, characterized by fibroblast activation and decreased epithelial marker E-cadherin in tumor cells. Interestingly, tumor cells and fibroblasts migrate together, with tumor cells in forming a center surrounded by fibroblasts, maximizing the contact between cells. We show a different mechanism for tumor spread through a cooperative migration between tumor cells and activated fibroblasts. Furthermore, IL-6 levels change significantly in coculture conditions, and this could affect the invasive and migratory capacities of cells. Targeting the interaction between tumor cells and the tumor microenvironment might represent a novel therapeutic approach to advanced PDAC.

1 June 2022 in Nanomedicine
Verified
Journal Article
Closed access
EVEdith Velázquez-Lam
Edith Velázquez-Lam
JTJaime Tome-Amat
Jaime Tome-Amat
CSCarmen Segrelles
Carmen Segrelles
CYCarmen Yuste-Calvo
Carmen Yuste-Calvo
Sara Asensio PeñaSara Asensio Peña
Sara Asensio Peña
CLCorina Lorz
Corina Lorz
Background: Filamentous plant virus-derived nanoparticles are biodegradable and noninfectious to humans. Their structure is also amenable to chemical modifications. They constitute an appealing mat... Plain language summary Cancer is the second leading cause of death worldwide, just behind cardiovascular disease. It accounts for nearly 10 million deaths annually, and new strategies to improve ea... Graphical abstract

Verified
Journal Article
Open access
PDF file
IGInés García-Consuegra
Inés García-Consuegra
Sara Asensio PeñaSara Asensio Peña
Sara Asensio Peña
RGRocio Garrido-Moraga
Rocio Garrido-Moraga
TPTomás Pinós
Tomás Pinós
CDCristina Domínguez-González
Cristina Domínguez-González
Miguel A. MartinMiguel A. Martin
Miguel A. Martin
Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.

2 November 2023 in Blood
Verified
Journal Article
Open access
SFSara Fernández-Luis
Sara Fernández-Luis
ABArancha Bermudez
Arancha Bermudez
LSLucrecia Yanez San Segundo
Lucrecia Yanez San Segundo
MGMónica Baile González
Mónica Baile González
Sara Asensio PeñaSara Asensio Peña
Sara Asensio Peña
ABAnna Maria Sureda Balari
Anna Maria Sureda Balari
Disclosures. Bermudez:GSK: Speakers Bureau; Janssen: Speakers Bureau; Amgen: Speakers Bureau; Pfizer: Speakers Bureau; NEOVII: Speakers Bureau; Sanofi: Speakers